Title: The AMPK activator ATX-304 alters cellular metabolism to protect against cisplatin-induced acute kidney injury
Authors: Katerelos, M
Gleich, K
Harley, G
Loh, K
Oakhill, JS
Kemp, BE
de Souza, DP
Narayana, VK
Coughlan, MT
Laskowski, A
Ling, NXY
Murray-Segal, L
Brink, R
Lee, M
Power, DA
Mount, PF
Issue Year: 2024
Publisher ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
Series BIOMEDICINE & PHARMACOTHERAPY:
Abstract Acute kidney injury (AKI) disrupts energy metabolism. Targeting metabolism through AMP -activated protein kinase (AMPK) may alleviate AKI. ATX-304, a pan-AMPK activator, was evaluated in C57Bl/6 mice and tubular epithelial cell (TEC) cultures. Mice received ATX-304 (1 mg/g) or control chow for 7 days before cisplatininduced AKI (CI-AKI). Primary cultures of tubular epithelial cells (TECs) were pre-treated with ATX-304 (20 mu M, 4 h) prior to exposure to cisplatin (20 mu M, 23 h). ATX-304 increased acetyl-CoA carboxylase phosphorylation, indicating AMPK activation. It protected against CI-AKI measured by serum creatinine (control 0.05 + 0.03 mM vs ATX-304 0.02 + 0.01 mM, P = 0.03), western blot for neutrophil gelatinase-associated lipocalin (NGAL) (control 3.3 + 1.8 -fold vs ATX-304 1.2 + 0.55 -fold, P = 0.002), and histological injury (control 3.5 + 0.59 vs ATX-304 2.7 + 0.74, P = 0.03). In TECs, pre-treatment with ATX-304 protected against cisplatinmediated injury, as measured by lactate dehydrogenase release, MTS cell viability, and cleaved caspase 3 expression. ATX-304 protection against cisplatin was lost in AMPK-null murine embryonic fibroblasts. Metabolomic analysis in TECs revealed that ATX-304 (20 mu M, 4 h) altered 66/126 metabolites, including fatty acids, tricarboxylic acid cycle metabolites, and amino acids. Metabolic studies of live cells using the XFe96 Seahorse analyzer revealed that ATX-304 increased the basal TEC oxygen consumption rate by 38%, whereas maximal respiration was unchanged. Thus, ATX-304 protects against cisplatin-mediated kidney injury via AMPKdependent metabolic reprogramming, revealing a promising therapeutic strategy for AKI.
URI: https://publications.svi.edu.au/publications/9833
Other Identifiers 10.1016/j.biopha.2024.116730
Publication type Article